Search results
Results From The WOW.Com Content Network
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2 ][ 3 ][ 4 ] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5 ] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal ...
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic ...
Bell Atlantic - after merger with NYNEX, headquarters moved from Philadelphia to New York City; a significant workforce remains in the area; Breyers - acquired by Kraft Foods and then by Unilever; Jones Apparel Group - moved to New York City; Whitman's - now operated by Russell Stover; based in Colorado
AstraZeneca reported earnings per share of $4.03, a year-over-year increase of 5%. In this way, Soriot said, the company is able to better "manage the turbulences" of the geopolitical landscape.
Website. www.medimmune.com [dead link] MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. [ 1][ 2] MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion. [ 3]
AstraZeneca has joined the legal fight against Medicare drug pricing negotiations, becoming the sixth pharmaceutical company, and first international company, to file ...
AstraZeneca is advancing early stage trials of several cell therapies in different types of cancer including liver and prostate cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak ...
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca , [ 33 ] [ 34 ] [ 35 ] using as a vector the modified ...